| Document |
Document Title |
|
WO/2020/054226A1 |
A thermal base generator is represented by formula (N1). This photosensitive resin composition contains the thermal base generator and a precursor of a heterocycle-containing polymer. In formula (N1), RN1 and RN2 each independently repre...
|
|
WO/2020/052179A1 |
Provided is a preparation process for an amantadine nitrate derivative. The preparation process comprises preparing the amantadine nitrate derivative from substituted or unsubstituted adamantane used as a raw material by means of the fol...
|
|
WO/2020/051099A1 |
The invention is concerned with the compounds of formula (I) and formula (II): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of using the compounds of formula (I) and formula (II) as...
|
|
WO/2020/047668A1 |
Provided herein are Myc-Max inhibitory compounds having the structure of Formula (I) and compositions thereof for use in the treatment of cancer. In particular, the Myc-Max inhibitory compounds may be useful for the treatment of cancers ...
|
|
WO/2020/047651A1 |
CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and poly-(ADP-ribose) polymerase (PARP) inhibitor. The CD47 blocking agent can be SIRPαFc and the PARP inhibitor niraparib. The anti-cancer ...
|
|
WO/2020/047168A1 |
The present invention is directed towards new chemical entities winch primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity, pa...
|
|
WO/2020/047399A1 |
Provided herein are lipidoid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions t...
|
|
WO/2020/040049A1 |
This composition includes a compound (A) represented by general formula (1) and a compound (B) represented by general formula (2), wherein the contained amount of the compound (B) is 0.00002-2.0 parts by mass with respect to 100 parts by...
|
|
WO/2020/040315A1 |
A method for stabilizing a sanshool compound is provided. The method for stabilizing a sanshool compound comprises a mixing step in which the sanshool compound is mixed with an antioxidant in a liquid, the liquid comprising water and/or ...
|
|
WO/2020/041301A1 |
Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the ...
|
|
WO/2020/040048A1 |
This composition includes a compound (A) represented by general formula (1) and a compound (B) represented by general formula (2), wherein the contained amount of the compound (B) is 0.00002-0.2 parts by mass with respect to 100 parts by...
|
|
WO/2020/040050A1 |
Provided are: a composition that has excellent stability during storage and excellent stability during use; and a production method for the composition. The composition according to the present invention includes a compound (A) represent...
|
|
WO/2020/040045A1 |
Provided are: a composition that has excellent stability during storage and excellent stability during use; and a production method for the composition. This composition includes a compound (A) represented by general formula (1), and a c...
|
|
WO/2020/039088A2 |
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...
|
|
WO/2020/034292A1 |
The present invention relates to the field of oil and gas field production increase transformations. Disclosed is a recyclable clean fracturing fluid thickening agent, a preparation method for same, a recycling method therefor, and a hig...
|
|
WO/2020/030931A1 |
The invention relates to a method of functionalising a diacetylene compound of formula (II) to form a diacetylene compound of formula (I): wherein x is from 1 to 20; Q is selected from an amide having the formula (IV) and an ester having...
|
|
WO/2020/025787A1 |
The invention relates to a process for the preparation of organo-iodinated compounds as well as the preparation intermediates thereof. More specifically, the invention relates to a process for the preparation of organo-iodinated compound...
|
|
WO/2020/020789A1 |
The invention relates to pharmaceutical dosage forms, which can be administered orally and have a modified release and contain sodium (3S)-3-(4-chloro-3-phenyl-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4
-trifluoro-3-methylbutanoyl]amino}phenyl)-...
|
|
WO/2020/020901A1 |
A method of forming a stable non-coloured or coloured state of a diacetylene compound having non-coloured, first coloured and second coloured states, the diacetylene compound being capable of transitioning from the non-coloured state to ...
|
|
WO/2020/020698A1 |
The invention relates to a process for preparing N-methyl(meth)acrylamide and to the uses thereof.
|
|
WO/2020/017557A1 |
Provided are: a compound suitable for imaging an intracerebral TRPV1 receptor; and a use thereof. A compound or a salt thereof represented by formula (I) is used. [In formula (1), R1 is a hydrogen or a random organic group; R2 is an orga...
|
|
WO/2020/009016A1 |
The present invention provides a method for producing an organic compound in which functional groups are reacted with each other without the use of a solvent. The present invention pertains to a method for producing an organic compound c...
|
|
WO/2020/006177A1 |
Disclosed herein are small molecule Vascular Adhesion Protein- 1 (VAP-1) modulator compositions, pharmaceutical compositions, the use and preparation thereof.
|
|
WO/2020/001298A1 |
Provided in the present invention are a 4-(p-trifluoromethylbenzyl)-3-floro-1,2,4 triphenylamine derivative, a pharmaceutical composition of same, and uses thereof. The chemical formula of the derivative is as represented by formula I, w...
|
|
WO/2020/006367A1 |
The invention provides methods and compositions for use in the prevention and treatment of antipsychotic medication-induced metabolic syndrome (MetS) and diseases and conditions related to MetS.
|
|
WO/2019/245008A1 |
The present invention addresses the problem of providing a new method for producing a compound including a fluoromethylene group. The problem is accomplished by a method for producing a compound represented by formula (1) (wherein R1 is ...
|
|
WO/2019/243799A1 |
The present disclosure relates to a hybrid salt/co-crystal of sacubitril. The present disclosure is also related to processes for the preparation of the hybrid salt/co-crystal of sacubitril. In addition, the present disclosure is related...
|
|
WO/2019/233375A1 |
Provided are a self-assembled amino acid supramolecular polymer and a preparation method therefor. Further provided is an application of the self-assembled amino acid supramolecular polymer in the fields of daily chemical, agricultural, ...
|
|
WO/2019/234728A1 |
The present invention provides THCA- and CBDA-derivatives, and pharmaceutical compositions thereof. These compounds are non-classical cannabinoids that are either agonists or antagonists of the peripheral CB1 and/or CB2 receptors, and ar...
|
|
WO/2019/233474A1 |
The present disclosure relates to compounds with antiviral activity, methods for the preparation ofsuch compounds, and their use to inhibit viral nucleoprotein activity, viral transcription, replication, and assembly into the newly forme...
|
|
WO/2019/233498A1 |
Provided are a cis-para-substituted cyclohexylamino nitrile salt as shown in formula (I) and a preparation method therefor, a use of said salt as a preparation intermediate for a pesticide such as spirotetramat, and a method for using sa...
|
|
WO/2019/228994A1 |
This invention relates to oleic acid derivative comprising a hydrophobic part C17H33 linked to a particular polar head part "A", especially for use as a medicament, for instance, for the treatment of a disorder caused by the GPR120 recep...
|
|
WO/2019/229625A1 |
The present invention relates to a process for the preparation of Apalutamide of formula (A) Apalutamide is a latest-generation androgen receptor inhibitor, used to treat non-metastatic castration-resistant prostate cancer.
|
|
WO/2019/229005A1 |
This invention relates to linoleic acid derivative of Formula (I) below comprising a hydrophobic part C17H 31 linked to a polar head part "A": (I) wherein said polar head part A is selected from A1 to A4 below: (ll) wherein R1 and R2 are...
|
|
WO/2019/231871A1 |
Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed h...
|
|
WO/2019/231870A1 |
Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed h...
|
|
WO/2018/177383A9 |
The present application relates to extracting, from a traditional Chinese medicine, a plurality of compounds capable of prompting nucleic acid delivery or synthetic compounds, and promoting nucleic acid such as sRNA to absorb and enter a...
|
|
WO/2019/224193A1 |
The invention relates to a method for preparing keto-functionalized aromatic (meth)acrylates by reacting keto-functionalized aromatic alcohols or keto-functionalized aromatic amines with (meth)acrylic anhydride having a content of (meth)...
|
|
WO/2019/221925A1 |
Provided herein are integrated systems and processes for more efficient use of raw materials in chemical synthesis of ammonia, urea and copolymers. The systems and processes may include nutrient fermentation, carbonylation of syngas deri...
|
|
WO/2019/216810A1 |
Compounds of the formulae wherein the bond α is a single bond, a trans double bond (E), or a triple bond; X and Y are -CH2- or on of X and Y is O and the other is CH2; R1 is phenyl unsubstituted or substituted with one, two, or three su...
|
|
WO/2019/216415A1 |
The present disclosure addresses the problem of providing a production method for a novel fluoromethyl derivative. The problem is solved by a production method that is for a fluorinated organic compound represented by formula (1) [in the...
|
|
WO/2019/205147A1 |
The present invention relates to an amino acetamide compound containing a benzo oxygen-containing aliphatic ring structure and a use thereof. In particular, disclosed are a compound represented by formula I or a pharmaceutically acceptab...
|
|
WO/2019/210008A1 |
The present disclosure relates to certain amides and heterocyclic compounds. The present disclosure also relates to uses of these compounds to inhibit Rho-associated protein kinases and treat diseases including autoimmune disorders, graf...
|
|
WO/2019/208705A1 |
A method for producing an N, N-disubstituted amide according to the present invention causes a reaction of a nitrile and an alcohol in the presence of a catalyst. This method for producing an N, N-disubstituted amide is configured such t...
|
|
WO/2019/200450A1 |
Methods for enhancing the activity of an ion transporter in a cell and/or treating a channelopathy in a subject based on the administration or use of an effective amount of a fenretinide compound (fenretinide, a fenretinide analog, or a ...
|
|
WO/2019/204180A1 |
Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed h...
|
|
WO/2019/197274A1 |
It is described an industrially viable and advantageous process for the preparation of mixed µOR agonist/δOR antagonists (9). The invention also discloses the intermediates obtained in the process.
|
|
WO/2019/196945A1 |
Disclosed is a novel method for synthesizing deuterated amides and deuterated sulfonamides, the steps being as follows: (1) adding a compound M, DMAP, R3-X to a solvent to obtain a compound N after a reaction is complete; (2) adding the ...
|
|
WO/2019/196714A1 |
An N-substituted acrylamide derivative, represented by general formula I, as a DHODH inhibitor, and preparation and use thereof. The N-substituted acrylamide derivative has excellent DHODH inhibiting activity, and thus can be used for tr...
|
|
WO/2019/195634A1 |
Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, B, L, R3, R4, R5, R6, R8, m and n are as defined herein. Such compounds...
|
